NASDAQ: ARQTArcutis Biotherapeutics Inc Stock
$26.66+0.45 (+1.72%)
Updated Jun 22, 2026
ARQT Price
$26.66
Fair Value Price
N/A
Market Cap
$3.33B
52 Week Low
$13.06
52 Week High
$31.77
P/E
-888.67x
P/B
17.58x
P/S
7.33x
PEG
N/A
Dividend Yield
N/A
Revenue
$415.62M
Earnings
-$2.38M
Gross Margin
90.9%
Operating Margin
2.91%
Profit Margin
-0.6%
Debt to Equity
1.43
Operating Cash Flow
$27M
Beta
1.23
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ARQT Overview
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARQT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ARQT
Ranked#47 of 467
Ranked#47 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.92 | A | |
| $51.35 | A | |
| $2.16 | A |
Be the first to know about important ARQT news, forecast changes, insider trades & much more!
ARQT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARQT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARQT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ARQT is poor value based on its book value relative to its share price (17.58x), compared to the US Biotechnology industry average (5.1x)
P/B vs Industry Valuation
ARQT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ARQT due diligence checks available for Premium users.
Valuation
ARQT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-888.67x
Industry
15.1x
Market
7.94x
ARQT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
17.58x
Industry
5.1x
ARQT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARQT's financial health
Profit margin
Revenue
$105.4M
Net Income
-$11.3M
Profit Margin
-10.7%
ARQT's Earnings (EBIT) of $12.08M... subscribe to Premium to read more.
Interest Coverage Financials
ARQT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$460.0M
Liabilities
$270.4M
Debt to equity
1.43
ARQT's short-term assets ($438.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARQT's short-term assets ($438.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARQT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ARQT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.2M
Investing
-$11.3M
Financing
$1.1M
ARQT's operating cash flow ($26.99M)... subscribe to Premium to read more.
Debt Coverage Financials
ARQT vs Biotech Stocks
Arcutis Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.